**2-(1H-benzimidazol-2-ylthio)-1-(2,3-dimethyl-1-indolyl)ethanone** is a chemical compound with a complex structure containing a benzimidazole ring, an indole ring, and a sulfur atom.
**Importance for Research:**
This compound is not widely known or studied, and there is limited information available about its specific research significance. However, its structure and chemical properties suggest potential applications in various fields:
* **Pharmacology:**
* **Antimicrobial activity:** The benzimidazole and indole moieties are known for their antimicrobial properties. This compound could potentially exhibit activity against bacteria, fungi, or parasites.
* **Anti-inflammatory activity:** Indole derivatives are often associated with anti-inflammatory effects. The compound could be investigated for its potential to reduce inflammation.
* **Other biological activities:** The presence of sulfur and the unique structure might confer other biological activities, such as antioxidant or enzyme inhibition properties.
* **Materials Science:**
* **Organic electronics:** The presence of aromatic rings and sulfur could contribute to the compound's conductivity and optical properties, making it potentially useful in organic electronics or optoelectronic devices.
**Further Research:**
To fully understand the importance of 2-(1H-benzimidazol-2-ylthio)-1-(2,3-dimethyl-1-indolyl)ethanone, further research is needed. This could involve:
* **Synthesis and characterization:** Developing efficient synthetic routes to produce the compound and thoroughly characterizing its chemical and physical properties.
* **Biological evaluation:** Conducting in vitro and in vivo studies to assess its biological activities, including antimicrobial, anti-inflammatory, and other potential therapeutic effects.
* **Structure-activity relationship (SAR) studies:** Modifying the compound's structure and evaluating the impact on its activity to identify the key structural features responsible for its biological effects.
**Conclusion:**
While the specific research importance of 2-(1H-benzimidazol-2-ylthio)-1-(2,3-dimethyl-1-indolyl)ethanone is currently unknown, its unique structure suggests potential applications in various fields, particularly in pharmacology and materials science. Further research is necessary to fully explore its potential.
ID Source | ID |
---|---|
PubMed CID | 704124 |
CHEMBL ID | 1304345 |
CHEBI ID | 121492 |
Synonym |
---|
EU-0080008 |
MLS000535320-02 |
MLS000535320 , |
smr000142756 |
2-{[2-(2,3-dimethyl-1h-indol-1-yl)-2-oxoethyl]thio}-1h-benzimidazole |
OPREA1_654835 |
2-(1h-benzimidazol-2-ylsulfanyl)-1-(2,3-dimethyl-1h-indol-1-yl)ethanone |
STK002455 |
CHEBI:121492 |
AKOS001667837 |
2-(1h-benzimidazol-2-ylsulfanyl)-1-(2,3-dimethylindol-1-yl)ethanone |
CHEMBL1304345 |
CCG-113278 |
HMS2342D18 |
bdbm82647 |
2-(1h-benzimidazol-2-ylthio)-1-(2,3-dimethyl-1-indolyl)ethanone |
2-(1h-benzimidazol-2-ylthio)-1-(2,3-dimethylindol-1-yl)ethanone |
cid_704124 |
sr-01000503893 |
SR-01000503893-1 |
Q27210044 |
433973-32-1 |
Class | Description |
---|---|
methylindole | Any member of the class of indoles carrying one or more methyl substituents. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 14.1254 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 9.5056 | 0.0040 | 23.8416 | 100.0000 | AID485290; AID489007 |
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 70.7946 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 31.5042 | 0.1259 | 19.1169 | 125.8920 | AID2549; AID2708; AID504841 |
Chain A, Cruzipain | Trypanosoma cruzi | Potency | 39.8107 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
WRN | Homo sapiens (human) | Potency | 26.6795 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 35.4813 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 28.1838 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 50.1187 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
DNA polymerase beta | Homo sapiens (human) | Potency | 8.9125 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 58.6829 | 0.1000 | 28.9256 | 213.3130 | AID588591; AID720502 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 73.7218 | 0.0501 | 27.0736 | 89.1251 | AID588590; AID720496 |
DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 12.7657 | 31.6228 | AID881 |
Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 25.1189 | 0.0063 | 8.2350 | 39.8107 | AID881 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
tyrosine-protein phosphatase non-receptor type 11 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 0.6030 | 0.1600 | 3.3759 | 9.8800 | AID602367 |
dual specificity protein phosphatase 3 | Homo sapiens (human) | IC50 (µMol) | 1.8100 | 0.4000 | 9.3610 | 90.0000 | AID602374 |
tyrosine-protein phosphatase non-receptor type 5 isoform a | Homo sapiens (human) | IC50 (µMol) | 44.9550 | 4.1700 | 12.5457 | 19.0000 | AID602372; AID624207 |
tyrosine-protein phosphatase non-receptor type 22 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 8.3270 | 0.4800 | 2.6449 | 8.3270 | AID624241 |
Vif | Human immunodeficiency virus 1 | IC50 (µMol) | 39.7000 | 0.2700 | 34.0015 | 100.0000 | AID1117319 |
Tat | Human immunodeficiency virus 1 | IC50 (µMol) | 100.0000 | 0.9960 | 39.8009 | 100.0000 | AID1117361 |
carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 3.3650 | 2.0580 | 8.2052 | 41.3880 | AID540297 |
DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | IC50 (µMol) | 39.7000 | 0.2700 | 26.3638 | 100.0000 | AID1117319 |
bifunctional UDP-N-acetylglucosamine pyrophosphorylase/glucosamine-1-phosphate N-acetyltransferase | Mycobacterium tuberculosis H37Rv | IC50 (µMol) | 38.2100 | 3.9100 | 83.9944 | 180.9200 | AID1376 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
iron ion binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
calcium ion binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
protein binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
lipid binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
linoleate 13S-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
arachidonate 8(S)-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
arachidonate 15-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
linoleate 9S-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
nucleus | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
cytosol | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
cytoskeleton | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
plasma membrane | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
adherens junction | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
focal adhesion | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
membrane | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
extracellular exosome | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |